Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) -negative and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

Journal of Clinical Oncology

Volumn 34, Issue 20, 2016, Pages 2416-2427

  Denduluri, Neelima ^a   Somerfield, Mark R ^c   Eisen, Andrea ^d   Holloway, Jamie N ^b   Hurria, Arti ^e   King, Tari A ^g   Lyman, Gary H ⁱ   Partridge, Ann H ^h   Telli, Melinda L ^f   Trudeau, Maureen E ^d   Wolff, Antonio C ^j  

^a US Oncology   (United States)

^b Patient Representative   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^d CANCER CARE ONTARIO   (Canada)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY   (United States)

^g DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ Fred Hutchinson Cancer Research Center   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PACLITAXEL; PERTUZUMAB; PLATINUM; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN;

ADD ON THERAPY; ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); DRUG CONTRAINDICATION; DRUG TOLERABILITY; EVIDENCE BASED PRACTICE; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; BREAST NEOPLASMS; CHEMISTRY; FEMALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RECEPTOR, ERBB-2;

EID: 84977492594     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.0182     Document Type: Article

References (32)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Peto R, Davies C, Godwin J, et al: Comparisons between different polychemotherapy regimens for early breast cancer:Meta-analyses of long-termoutcome among 100,000 women in 123 randomised trials. Lancet 379:432-444, 2012
3. Gandhi S, Fletcher GG, Eisen A, et al: Adjuvant chemotherapy for early female breast cancer: A systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 22:S82-S94, 2015 (suppl 1)
4. Eisen A, Fletcher GG, Gandhi S, et al: Optimal systemic therapy for early breast cancer in women: A clinical practice guideline. Curr Oncol 22:S67-S81, 2015 (suppl 1)
5. Shulman LN, Berry DA, Cirrincione CT, et al: Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol 32:2311-2317, 2014
6. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
7. Muss HB, Berry DA, Cirrincione CT, et al: Adjuvant chemotherapy in older women with earlystage breast cancer. N Engl J Med 360:2055-2065, 2009
8. Jones SE, Savin MA, Holmes FA, et al: Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381-5387, 2006
9. Jones S, Holmes FA, O'Shaughnessy J, et al: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27:1177-1183, 2009
10. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
11. O'Sullivan CC, Bradbury I, Campbell C, et al: Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2-positive early breast cancer and tumors ≤ 2 cm: A metaanalysis of the randomized trastuzumab trials. J Clin Oncol 33:2600-2608, 2015
12. Tolaney SM, Barry WT, Dang CT, et al: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372: 134-141, 2015
13. Jones SE, Collea R, Paul D, et al: Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: A single-group, open-label, phase 2 study. Lancet Oncol 14:1121-1128, 2013
14. Chia S, Norris B, Speers C, et al: Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 26:5697-5704, 2008
15. Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
16. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
17. Vaz-Luis I, Ottesen RA, Hughes ME, et al: Outcomes by tumor subtype and treatment pattern in womenwith small, node-negative breast cancer: Amultiinstitutional study. J Clin Oncol 32:2142-2150, 2014
18. Buzdar AU, Suman VJ, Meric-Bernstam F, et al: Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): A randomised, controlled, phase 3 trial. Lancet Oncol 14:1317-1325, 2013
19. Perez EA, Suman VJ, Davidson NE, et al: Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29:4491-4497, 2011
20. Gianni L, Dafni U, Gelber RD, et al: Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244, 2011
21. Cortazar P, Zhang L, Untch M, et al: Pathological complete response and long-term clinical benefit in breast cancer: The CTNeo BC pooled analysis. Lancet 384:164-172, 2014
22. Isakoff SJ, Mayer EL, He L, et al: TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33: 1902-1909, 2015
23. Tutt A, Ellis P, Kilburn L, et al: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res 75, 2015 (suppl 9; abstr S3-01) doi:10.1158/1538-7445.SABCS14-S3-01
24. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153, 2010
25. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
26. Alba E, Chacon JI, Lluch A, et al: A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting: Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 136:487-493, 2012
27. Sikov WM, Berry DA, Perou CM, et al: Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13-21, 2015
28. Sikov WM, Berry DA, Perou C, et al: Eventfree and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance). Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2015
29. von Minckwitz G, Schneeweiss A, Loibl S, et al: Neoadjuvant carboplatin in patients with triplenegative and HER2-positive early breast cancer (Gepar Sixto; GBG 66): A randomised phase 2 trial. Lancet Oncol 15:747-756, 2014
30. Von Minckwitz G, Loibl S, Schneeweiss A, et al: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2015
31. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
32. Hurria A, Levit LA, Dale W, et al: Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology Statement. J Clin Oncol 33:3826-3833, 2015